Hyperfractionated radiotherapy improves overall survival in patients with head and neck cancer

the ONA take:

A multi-institutional, randomized phase III trial of fractionation in locally advanced head and neck cancer demonstrated improved local-regional control and improved overall survival with no increase in late toxicity with hyperfractionated radiation therapy (HFX). Patients enrolled in the study, RTOG 9003, were 18 years or older and have previously untreated, locally advanced squamous cell cancers of the oral cavity, oropharynx or supraglottic larynx in stage III or IV or stage II-IV carcinoma of the base of the tongue or hypopharynx. Patients were randomized to four different treatment arms; all treatments were delivered 5 days a week, and twice-daily treatments had a minimum interfraction interval of 6 hours. At 5 years posttreatment, patients in the HFX arm had the highest overall survival rates.

Hyperfractionated radiotherapy improves overall survival in patients with head and neck cancer
Hyperfractionated radiotherapy improves overall survival in patients with head and neck cancer
Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity.
READ FULL ARTICLE From News Medical
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs